Voyager Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Voyager Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Cash, after subtracting all debt, is 1.4 times its market value (net cash). Higher than 92% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-7.5×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Higher than 52% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 1/3Sales grew in 1 of the last 3 years; profit grew in 1 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales barely changed
Sales changed by -1% in 3 years, too little to measure extra profit per extra sales.
Asset Productivity Ratio
-1% / +58%In 3 years sales changed by -1% while total assets changed by +58%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-16.9×Operating cash was negative last year, while some debt falls due within a year.
Lower than 51% of Healthcare companies in United States.
Cash Cushion Ratio
1.4× cashCash, after subtracting all debt, is 1.4 times its market value (net cash).
Higher than 92% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Voyager Therapeutics, Inc. made a loss over the last year. Voyager Therapeutics, Inc. owes $0.22 for every $1 it owns. Voyager Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossVoyager Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.74The share price is 0.74 times Voyager Therapeutics, Inc.'s book value per share, lower than 85% of Healthcare companies in United States.
Market cap
$115 MThe total market value of all of Voyager Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 64% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$154 MWhat Voyager Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$2.51Net worth divided by the number of shares. The share price of $1.86 is 0.7 times this, which is the P/B above.
Return on equity (ROE)
-54.1%Voyager Therapeutics, Inc. lost 54.1% of its shareholders' money over the last year, lower than 53% of Healthcare companies in United States.
Owes vs Owns
0.22×Voyager Therapeutics, Inc. owes $0.22 for every $1 it owns (low), lower than 70% of Healthcare companies in United States.
Dividend yield
NoneVoyager Therapeutics, Inc. does not currently pay a dividend.
Revenue growth
-50%Revenue fell 50% in the year to Dec 2025, and shrank 0% a year on average over 3 years.
Profit growth
LossVoyager Therapeutics, Inc. made a loss in each of the last two years.
Profit margin
-296.5%Voyager Therapeutics, Inc. lost $297 for every $100 of revenue.
Cash vs debt
Net cashVoyager Therapeutics, Inc. held $160 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Voyager Therapeutics, Inc.: $115 M ÷ $154 M (30 Jun 2026) = 0.7.
What is Voyager Therapeutics, Inc.'s return on equity?
Voyager Therapeutics, Inc. lost 54.1% of its shareholders' money over the last year, lower than 53% of Healthcare companies in United States.
How much does Voyager Therapeutics, Inc. owe compared with what it owns?
Voyager Therapeutics, Inc. owes $0.22 for every $1 it owns (low), lower than 70% of Healthcare companies in United States.
Does Voyager Therapeutics, Inc. pay a dividend?
No. Voyager Therapeutics, Inc. does not currently pay a dividend.
Is Voyager Therapeutics, Inc.'s revenue growing?
Revenue fell 50% in the year to Dec 2025, and shrank 0% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.